Introduction {#bjs11115-sec-0005}
============

Surgical resection in combination with (neo)adjuvant chemotherapy is the only potentially curative treatment for patients with pancreatic ductal adenocarcinoma (PDAC). Overall survival (OS) among patients with PDAC is poor[1](#bjs11115-bib-0001){ref-type="ref"}. This may be related to incomplete resection of the tumour and a consequence of high recurrence rates[2](#bjs11115-bib-0002){ref-type="ref"}, [3](#bjs11115-bib-0003){ref-type="ref"}, [4](#bjs11115-bib-0004){ref-type="ref"}. Other factors affecting outcome include tumour size[5](#bjs11115-bib-0005){ref-type="ref"}, perineural and/or lymphangioinvasion[6](#bjs11115-bib-0006){ref-type="ref"} and lymph node status[6](#bjs11115-bib-0006){ref-type="ref"}, [7](#bjs11115-bib-0007){ref-type="ref"}, [8](#bjs11115-bib-0008){ref-type="ref"}. Resection margin (R) status remains the most controversial[4](#bjs11115-bib-0004){ref-type="ref"}. Over two decades ago, Yeo and colleagues[9](#bjs11115-bib-0009){ref-type="ref"} reported that patients who underwent radical pancreatoduodenectomy with tumour‐free resection margins (R0) had a 5‐year survival rate of 26 per cent, compared with only 8 per cent in those with positive margins (R1)[9](#bjs11115-bib-0009){ref-type="ref"}. Ghaneh and co‐workers[10](#bjs11115-bib-0010){ref-type="ref"} reported a difference in median survival between R0 and R1 resection (24·9 *versus* 18·7 months respectively) in a large multicentre RCT.

Other studies[11](#bjs11115-bib-0011){ref-type="ref"}, [12](#bjs11115-bib-0012){ref-type="ref"}, [13](#bjs11115-bib-0013){ref-type="ref"}, [14](#bjs11115-bib-0014){ref-type="ref"} have reported that resection margin status is not an independent risk factor for survival. An explanation could be the lack of standardized pathological evaluation of the specimen, or definition and reporting of resection margin status[15](#bjs11115-bib-0015){ref-type="ref"}, [16](#bjs11115-bib-0016){ref-type="ref"}. For example, in the USA, a resection margin is considered positive when tumour cells have reached the inked margin[9](#bjs11115-bib-0009){ref-type="ref"}, [17](#bjs11115-bib-0017){ref-type="ref"}. In Europe, a positive resection margin is defined by the presence of tumour cells within 1 mm of the resection margin[15](#bjs11115-bib-0015){ref-type="ref"}, [18](#bjs11115-bib-0018){ref-type="ref"}, [19](#bjs11115-bib-0019){ref-type="ref"}. This discrepancy has led to a wide range of reported rates of resection margin involvement from less than 20 per cent to more than 75 per cent[18](#bjs11115-bib-0018){ref-type="ref"}, [20](#bjs11115-bib-0020){ref-type="ref"}, [21](#bjs11115-bib-0021){ref-type="ref"}, [22](#bjs11115-bib-0022){ref-type="ref"}, [23](#bjs11115-bib-0023){ref-type="ref"}, [24](#bjs11115-bib-0024){ref-type="ref"}. Recently, Osipov and colleagues[25](#bjs11115-bib-0025){ref-type="ref"} reported favourable disease‐free survival and OS after R0 resection, defined by the presence of tumour cells within 0·5 mm up to 2 mm from the resection margin. These results support the findings of Chang *et al*.[26](#bjs11115-bib-0026){ref-type="ref"} and Gebauer and co‐workers[27](#bjs11115-bib-0027){ref-type="ref"}, who also recommended a resection margin of 1·5 or 2 mm.

An alternative hypothesis suggests that recurrence following R1 resection is not due to residual tumour cells, but reflects an aggressive tumour biology[28](#bjs11115-bib-0028){ref-type="ref"}, [29](#bjs11115-bib-0029){ref-type="ref"}. This is based on the finding that isolated locoregional recurrence (LRR) without distant metastases is found in only 10--25 per cent of patients[11](#bjs11115-bib-0011){ref-type="ref"}, [30](#bjs11115-bib-0030){ref-type="ref"}.

The aims of this study were to examine the impact of a positive resection margin on recurrence and survival; and to assess which tumour characteristics and/or technical factors are associated with R1 resection status in patients with PDAC.

Methods {#bjs11115-sec-0006}
=======

This retrospective study was approved by the Institutional Medical Ethics Committee at Leiden University Medical Centre (LUMC), Leiden, the Netherlands. Patients with a histological diagnosis of PDAC who were scheduled for curative pancreatic resection between January 2006 and December 2016 were identified from an electronic institutional database. Follow‐up data were collected until October 2017. Patients with any other histopathological diagnosis were excluded, including those with malignant intraductal papillary mucinous neoplasms. Operative data and patient characteristics were collected in the database, including age at time of surgery, sex and type of surgery. Tumour characteristics recorded were: pTNM stage, grade, histopathological diagnosis, lymph node involvement, total number of resected lymph nodes, lymph node ratio, and lymphangioinvasion and/or perineural invasion.

After preoperative evaluation, including measurement of carbohydrate antigen 19.9 and carcinoembryonic antigen levels, contrast‐enhanced CT, and MRI and/or endoscopic ultrasonography where indicated, a multidisciplinary team of pancreatic surgeons, radiologists, gastroenterologists, pathologists and oncologists decided whether surgery with curative intent was feasible. The criteria for a non‐resectable tumour were: presence of distant metastases; obvious involvement of coeliac and/or para‐aortic nodes; and contact with the superior mesenteric artery, common hepatic artery, coeliac trunk of more than 90°, or encasement of the superior mesenteric or portal vein. All tumours were classified before surgery as resectable or borderline resectable according to Dutch Pancreatic Cancer Group (DPCG) 2012 criteria (PREOPANC trial)[31](#bjs11115-bib-0031){ref-type="ref"}.

After surgery, each patient was discussed by the multidisciplinary team to determine whether adjuvant therapy was indicated. In the Netherlands, the standard for adjuvant chemotherapy is six cycles of gemcitabine. Because patients who undergo surgical resection receive adjuvant treatment at a site other than the referral hospital, detailed information regarding the dose, frequency and completeness of this planned treatment was not available. Therefore, the study included only whether each patient was recommended for adjuvant therapy or not. As neoadjuvant treatment is not standard of care and administered only in the context of clinical trials, patients who received neoadjuvant treatment were excluded.

Follow‐up information was obtained from the electronic patient records at LUMC, the primary care physician or the oncologist. Follow‐up imaging (primarily CT) was performed when indicated clinically; no standard protocol was used.

Recurrence was diagnosed based on evidence of disease on imaging. LRR was defined as the presence of disease in the surgical bed or present in the mesentery, periaortic soft tissue, pancreatojejunal anastomosis or in the nodes around the vena cava, coeliac axis and/or retroperitoneum. Distant metastasis was defined as the presence of disease in the omentum, peritoneum, solid organs and/or pelvic lymph nodes. Early recurrence was defined as recurrence occurring within 6 months after surgery[32](#bjs11115-bib-0032){ref-type="ref"}, [33](#bjs11115-bib-0033){ref-type="ref"}. Overall recurrence was defined as any form of recurrence (locoregional or distant) that occurred first during follow‐up.

Pathological assessment {#bjs11115-sec-0007}
-----------------------

Macroscopic and microscopic examination of the pancreatoduodenectomy specimen was done using standard methods in accordance with the guidelines established by DPCG, which followed the recommendations of Verbeke and colleagues[15](#bjs11115-bib-0015){ref-type="ref"}, [18](#bjs11115-bib-0018){ref-type="ref"}. Before 2010, examination was performed by bivalving the specimen. After the pancreas had been resected, the surgeon attached coloured beads to the different resection margins. Subsequently, the pathologist used multicolour inking of the specimen to identify these margins. The following terms were used to define the resection margins: posterior, vascular (superior mesenteric vein or superior mesenteric artery), common bile duct, anterior, pancreatic neck, caudal and circumferential margin. For analysis of the association between resection margin and outcome, only patients who had a Whipple\'s resection or pylorus‐preserving pancreatoduodenectomy (PPPD) were included.

Histological findings were reviewed to confirm the diagnosis, tumour characteristics and R status of the margins. Staging was determined using the TNM cancer staging system, seventh edition[34](#bjs11115-bib-0034){ref-type="ref"}. R1 resection was defined in accordance with Dutch guidelines, which were in line with the guidelines of the British Royal College of Pathology ([https://www.rcpath.org/profession/guidelines/cancer‐datasets‐and‐tissue‐pathways.html](https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html)); a surgical margin with malignant cells identified 1 mm or less from the inked margin was considered positive. A random sample of histological specimens was re‐examined.

Statistical analysis {#bjs11115-sec-0008}
--------------------

Student\'s *t* test was used for analysis of continuous data with a normal distribution and the Mann--Whitney *U* test for data with a skewed distribution; categorical data were compared using the χ^2^ test. OS was calculated as the interval between either the date of death (event) or last follow‐up (censored) and the date of surgery, and is reported as median with 95 per cent confidence intervals. Time to recurrence was calculated as the interval between the date of surgery and the date of diagnosis of LRR or distant metastasis. The overall time to recurrence was calculated as the interval between date of surgery and first recurrence, either LRR or distant metastasis. If a patient died without evidence of recurrence (censored), the date of last follow‐up imaging or last follow‐up without clinical signs of recurrent disease was used. Therefore, death was not a competing risk in the analyses. Kaplan--Meier analysis and the log rank test were used to evaluate differences in recurrence and survival between groups. Characteristics associated with recurrence or survival were included in a Cox proportional hazards regression analysis. Differences were considered statistically significant at *P* \< 0·050. SPSS® Statistics for Windows® version 23.0 was used for statistical analysis (IBM, Armonk, New York, USA).

Results {#bjs11115-sec-0009}
=======

Some 322 patients underwent pancreatic resection (275 Whipple\'s procedure or PPPD, 35 distal pancreatectomy, 12 total pancreatectomy). A further 148 patients (31·5 per cent) underwent laparotomy with or without palliative bypass surgery owing to distant metastases or non‐resectable disease. Patient characteristics according to resection margin status are shown in *Table* [1](#bjs11115-tbl-0001){ref-type="table"}. Before adopting the so‐called Verbeke protocol for gross examination of pancreas specimens (from 2006 to 2009), the R1 resection rate was 32 per cent (22 of 68); from 2010 onwards, the R1 resection rate was 42·1 per cent (107 of 254) (*P =* 0·144). Some 45 specimens were re‐examined randomly, with no change in R status. Median survival following resection was 18 (95 per cent c.i. 16 to 20) months.

###### 

Patient characteristics according to resection margin

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                             All patients\        R0\                R1\            *P* [§](#bjs11115-note-0005){ref-type="fn"}
                                                                              (*n* = 322)     (*n* = 193)        (*n* = 129)     
  ------------------------------------------------------------------------- --------------- ---------------- ------------------- --------------------------------------------------
  **Age (years)** [\*](#bjs11115-note-0002){ref-type="fn"}                      65(10)           66(10)             64(9)           0·172[¶](#bjs11115-note-0006){ref-type="fn"}

  **Sex ratio (M : F)**                                                        161: 161          95: 98            66: 63                              0·733

  **Death**                                                                   231 (71·7)       130 (67·4)        101 (78·3)                            0·033

  **Survival (months)** [†](#bjs11115-note-0003){ref-type="fn"}               18 (16, 20)     22 (17, 27)        15 (13, 17)      \< 0·001[\#](#bjs11115-note-0007){ref-type="fn"}

  **Tumour size (mm)** [\*](#bjs11115-note-0002){ref-type="fn"}                 29(15)           26(15)            33(15)         \< 0·001[¶](#bjs11115-note-0006){ref-type="fn"}

  **Adjuvant therapy**                                                        172 (53·4)       95 (49·2)          77 (59·7)                            0·065

  **Tumour differentiation**                                                                                                                           0·564

  Well                                                                         63 (19·6)       40 (20·7)          23 (17·8)      

  Moderate                                                                    133 (41·3)       80 (41·5)          53 (41·1)      

  Poor                                                                        124 (38·5)       71 (36·8)          53 (41·1)      

  Undifferentiated                                                              2 (0·6)         2 (1·0)            0 (0·0)       

  **No. of resected lymph nodes** [‡](#bjs11115-note-0004){ref-type="fn"}     15 (11--20)     15 (11--19)        15 (12--21)      0·318[\*\*](#bjs11115-note-0008){ref-type="fn"}

  **Lymph node‐positive**                                                     222 (68·9)       122 (63·2)        100 (77·5)                            0·007

  **No. of positive lymph nodes** [‡](#bjs11115-note-0004){ref-type="fn"}      2 (0--4)         1 (0--3)          3 (1--5)        0·001[\*\*](#bjs11115-note-0008){ref-type="fn"}

  **Lymph node ratio** [‡](#bjs11115-note-0004){ref-type="fn"}               0·1 (0--0·28)   0·08 (0--0·25)   0·17 (0·04--0·31)   0·003[\*\*](#bjs11115-note-0008){ref-type="fn"}

  **Tumour stage**                                                                                                                                    \< 0·001

  IA                                                                           27 (8·4)        23 (11·9)           4 (3·1)       

  IB                                                                           11 (3·4)         9 (4·7)            2 (1·6)       

  IIA                                                                          59 (18·3)       40 (20·7)          19 (14·7)      

  IIB                                                                         207 (64·3)       118 (61·1)         89 (69·0)      

  III                                                                          15 (4·7)         2 (1·0)           13 (10·1)      

  IV                                                                            3 (0·9)         1 (0·5)            2 (1·6)       

  **Perineural invasion**                                                     201 (62·4)       104 (53·9)         97 (75·2)                           \< 0·001

  **Lymphangioinvasion**                                                       70 (21·7)       35 (18·1)          35 (27·1)                            0·055
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values in parentheses are percentages unless indicated otherwise; values are

mean(s.d.),

median (95 per cent c.i.) and

median (i.q.r.). R0, resection margin free from tumour cells; R1, tumour cells within 1 mm of resection margin.

χ^2^ test, except

Student\'s *t* test,

log rank test and

Mann--Whitney *U* test.

Impact of R1 status on tumour recurrence {#bjs11115-sec-0010}
----------------------------------------

Of patients who underwent pancreatectomy, 196 (60·9 per cent) developed a recurrence: 45 (14·0 per cent) had LRR, 91 (28·3 per cent) distant metastasis, and 60 (18·6 per cent) developed both LRR and distant metastasis. Fifty‐five of the 196 patients (28·1 per cent) whose disease relapsed had an early recurrence within 6 months after surgery. Patients with early recurrence had a non‐significantly higher tumour stage, more tumour‐positive lymph nodes and a higher prevalence of perineural invasion than patients without early recurrence (*Table* [2](#bjs11115-tbl-0002){ref-type="table"}). In patients who developed distant metastasis, liver metastases were more prevalent in the early recurrence group (39 of 55 (71 per cent) *versus* 60 of 267 (22·5 per cent); *P* \< 0·001).

###### 

Patient characteristics according to time until recurrence

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                             Recurrence within 6 months\   All other patients\     *P* [‡](#bjs11115-note-0012){ref-type="fn"}
                                                                                     (*n* = 55)                (*n* = 267)      
  ------------------------------------------------------------------------- ----------------------------- --------------------- -------------------------------------------------
  **Age (years)** [\*](#bjs11115-note-0010){ref-type="fn"}                             64(10)                    66(10)           0·150[§](#bjs11115-note-0013){ref-type="fn"}

  **Sex ratio (M : F)**                                                                29: 26                   132: 135                              0·657

  **Death**                                                                            53 (96)                 178 (66·7)                           \< 0·001

  **Survival (months)** [†](#bjs11115-note-0011){ref-type="fn"}                           8                        23            \< 0·001[¶](#bjs11115-note-0014){ref-type="fn"}

  **Tumour size (mm)** [\*](#bjs11115-note-0010){ref-type="fn"}                        32(14)                    28(16)           0·083[§](#bjs11115-note-0013){ref-type="fn"}

  **Adjuvant therapy**                                                                 23 (42)                 149 (55·8)                             0·058

  **Tumour differentiation**                                                                                                                          0·078

  Well                                                                                 6 (11)                   57 (21·3)       

  Moderate                                                                             20 (36)                 113 (42·3)       

  Poor                                                                                 29 (53)                  95 (35·6)       

  Undifferentiated                                                                      0 (0)                    2 (0·7)        

  **Lymph node‐positive**                                                              43 (78)                 179 (67·0)                             0·104

  **No. of positive lymph nodes** [‡](#bjs11115-note-0012){ref-type="fn"}             2 (0--4)                  2 (1--5)          0·125[\#](#bjs11115-note-0015){ref-type="fn"}

  **Tumour stage**                                                                                                                                    0·192

  IA                                                                                    2 (4)                   25 (9·4)        

  IB                                                                                    1 (2)                   10 (3·7)        

  IIA                                                                                  9 (16)                   50 (18·7)       

  IIB                                                                                  38 (69)                 169 (63·3)       

  III                                                                                   3 (5)                   12 (4·5)        

  IV                                                                                    2 (4)                    1 (0·4)        

  **Perineural invasion**                                                              40 (73)                 161 (60·3)                             0·083

  **Lymphangioinvasion**                                                               15 (27)                  55 (20·6)                             0·275

  **Resection margin**                                                                                                                                0·071

  R0                                                                                   27 (49)                 166 (62·2)       

  R1                                                                                   28 (51)                 101 (37·8)       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values in parentheses are percentages unless indicated otherwise; values are

mean(s.d.),

median (95 per cent c.i.) and ‡median (i.q.r.). R0, resection margin free from tumour cells; R1, tumour cells within 1 mm of resection margin.

χ^2^ test, except

Student\'s *t* test,

log rank test and

Mann--Whitney *U* test.

The median time until LRR was 16 (95 per cent c.i. 12 to 20) months in the R1 group compared with 36 (not estimated, n.e.) months in the R0 group (*P =* 0·002) (*Fig*. [1](#bjs11115-fig-0001){ref-type="fig"} *a*). The LRR rate was similar in the R1 (7 patients) and R0 (12) groups (approximately 8 per cent) in the first 6 months after resection. Time to diagnosis of distant metastasis was also significantly shorter after R1 resection (15 (11 to 19) *versus* 20 (13 to 27) months; *P =* 0·036) (*Fig*. [1](#bjs11115-fig-0001){ref-type="fig"} *b*). Finally, time until any recurrence was shorter in the R1 group (13 (10 to 16) *versus* 15 (12 to 18) months; *P* \< 0·001) (*Fig*. [1](#bjs11115-fig-0001){ref-type="fig"} *c*). LRR was associated significantly with perineural invasion (*P* = 0·031); the only significant predictor of distant metastasis was lymph node status (*P* = 0·001) (*Table* [S1](#bjs11115-supitem-0001){ref-type="supplementary-material"}, supporting information).

![Locoregional recurrence, distant metastasis and overall recurrence according to resection margin status\
**a** Locoregional recurrence (*P =* 0·002), **b** distant metastasis (*P =* 0·036) and **c** overall recurrence (*P* \< 0·001) (log rank test).](BJS-106-1055-g001){#bjs11115-fig-0001}

Involvement of surgical margins and outcome {#bjs11115-sec-0011}
-------------------------------------------

The vascular resection margin was involved with cancer cells in 56 of 107 patients (52·3 per cent) in the R1 group (*Table* [S2](#bjs11115-supitem-0001){ref-type="supplementary-material"}, supporting information). The location of the R1 margin had no statistically significant association with surgical outcomes including OS and LRR (*Fig*. [S1](#bjs11115-supitem-0001){ref-type="supplementary-material"} *a*,*c*, supporting information).

Influence of margin status on long‐term distribution patterns of recurrence {#bjs11115-sec-0012}
---------------------------------------------------------------------------

There was no statistically significant difference in the distribution pattern of metastases between the R0 and R1 groups (*Fig*. [2](#bjs11115-fig-0002){ref-type="fig"}). Some 41 of 277 patients (14·8 per cent) presented with distant metastasis within 5 months of surgery. Of 151 patients with distant metastasis, 38 (25·2 per cent) had liver metastases within 6 months after resection.

![Spatial distribution of locoregional recurrence and distant metastasis following resection\
**a** All patients, **b** after R0 resection, **c** after R1 resection. Percentages indicate the percentage of patients with recurrence at each site.](BJS-106-1055-g002){#bjs11115-fig-0002}

Correlation between margin status, tumour characteristics and outcome {#bjs11115-sec-0013}
---------------------------------------------------------------------

Patients who underwent R1 resection had a median OS of 15 (95 per cent c.i. 13 to 17) months compared with 22 (17 to 27) months among those who had R0 resection (*P* \< 0·001) (*Fig*. [3](#bjs11115-fig-0003){ref-type="fig"}). Multivariable analyses revealed that perineural invasion, tumour‐positive lymph node status (N1) and R1 resection were significant predictors of OS, with hazard ratios (HRs) of 1·44 (*P* = 0·016), 2·15 (*P* \< 0·001) and 1·37 (*P* = 0·031) respectively. Adjuvant chemotherapy had a protective effect on OS (HR 0·70; *P* = 0·012) (*Table*  [S3](#bjs11115-supitem-0001){ref-type="supplementary-material"}, supporting information).

![Overall survival according to resection margin status\
*P* \< 0·001 (log rank test).](BJS-106-1055-g003){#bjs11115-fig-0003}

Impact of surgical factors in patients with node‐negative disease {#bjs11115-sec-0014}
-----------------------------------------------------------------

A separate analysis was done in which patients were grouped into those with lymph node‐negative (R0 N0, 71; R1 N0, 29) or node‐positive (R0 N1, 122; R1 N1, 100) disease. LRR occurred significantly earlier in patients with R1 N0 (median 17 (95 per cent c.i. 9 to 25) months) and R1 N1 status (16 (12 to 20) months) than in the R0 groups (*Fig*. [4](#bjs11115-fig-0004){ref-type="fig"} *a*). Patients with R0 N0 status had a significantly longer interval until the development of distant metastasis (67 (n.e.) months) than the other patients (*Fig*. [4](#bjs11115-fig-0004){ref-type="fig"} *b*).

![Subgroup analysis of effect of margin status (R0 or R1) and lymph node status (N0 or N1) on locoregional recurrence, distant metastasis and overall survival\
**a** Locoregional recurrence (*P \<* 0·001), **b** distant metastases (*P \<* 0·001) and **c** overall recurrence (*P* \< 0·001) (log rank test).](BJS-106-1055-g004){#bjs11115-fig-0004}

Patients with R0 N0 disease had significantly longer OS (median 45 (n.e.) months) than those with R0 N1 (17 (95 per cent c.i. 15 to 19) months; *P* \< 0·001), R1 N0 (17 (10 to 24) months; *P* \< 0·001) or R1 N1 (14 (12 to 16) months; *P* \< 0·001) status (*Fig*. [4](#bjs11115-fig-0004){ref-type="fig"} *c*). Among patients with N0 tumours, OS was significantly worse after R1 compared with R0 resection (*P =* 0·002), although tumour characteristics were similar (*Table* [3](#bjs11115-tbl-0003){ref-type="table"}). For patients with N1 disease, OS was similar after R1 and R0 resection (*P =* 0·068).

###### 

Effect of tumour biology

                                                                   Lymph node‐negative (N0)   Lymph node‐positive (N1)                                                                         
  --------------------------------------------------------------- -------------------------- -------------------------- ---------------------------------------------- ----------- ----------- -------------------------------------------------
  **Perineural invasion**                                                  34 (48)                    16 (55)                               0·509                       70 (57·4)   81 (81·0)                      \< 0·001
  **Lymphangioinvasion**                                                    8 (11)                     6 (21)                               0·218                       27 (22·1)   29 (29·0)                         0·241
  **Tumour differentiation**                                                                                                                0·802                                                                     0·741
  Well                                                                     16 (23)                     6 (21)                                                           24 (19·7)   17 (17·0)  
  Moderate                                                                 25 (35)                    10 (34)                                                           55 (45·1)   43 (43·0)  
  Poor                                                                     28 (39)                    13 (45)                                                           43 (35·2)   40 (40·0)  
  Undifferentiated                                                          2 (3)                      0 (0)                                                              0 (0)       0 (0)    
  **Tumour size (mm)** [\*](#bjs11115-note-0017){ref-type="fn"}             27(20)                     27(18)            0·933[‡](#bjs11115-note-0019){ref-type="fn"}    26(12)      34(13)     \< 0·001[‡](#bjs11115-note-0019){ref-type="fn"}

Values in parentheses are percentages unless indicated otherwise; values are

mean(s.d). R0, resection margin free from tumour cells; R1, tumour cells within 1 mm of resection margin.

χ^2^ test, except

Student\'s *t* test.

Discussion {#bjs11115-sec-0015}
==========

This study showed a clear difference in OS and overall recurrence between patients who underwent pancreatectomy with negative resection margins and those with involved resection margins. A high recurrence rate within 6 months after surgery was found in both groups. This indicates the limitations of the current staging modalities used to exclude micrometastases and to select patients for curative surgery. This finding is clinically relevant as median OS among patients with early recurrence was only 8 months, compared with 11 months in patients who received palliative chemotherapy for non‐resectable or metastatic disease[35](#bjs11115-bib-0035){ref-type="ref"}. In pancreatic cancer surgery, the focus should be on improving the detection of distant disease and local resectability of the tumour as this could improve outcome following resection.

FOLFIRINOX (folinic acid, 5‐fluorouracil, irinotecan and oxaliplatin) chemotherapy for pancreatic cancer has an increasing role in downstaging the tumour and improving resection rates as well as representing a potent regimen for metastatic disease. The association between resection margin status and lymphangioinvasion and lymph node status suggests that the prognosis of tumours with aggressive biological characteristics may be improved by adding (neo)adjuvant therapy. Previous studies[28](#bjs11115-bib-0028){ref-type="ref"}, [29](#bjs11115-bib-0029){ref-type="ref"} reported that R1 status is probably not only a proxy for surgical quality but can also reflect the tumour\'s biological behaviour. In the present study, a difference was found in perineural invasion, tumour‐positive lymph nodes and tumour stage between the R0 and R1 groups. These results are similar to those of Kimbrough and colleagues[36](#bjs11115-bib-0036){ref-type="ref"}, who reported a significantly higher lymph node ratio and more microvascular invasion in the R1 group. This may also explain the present difference in OS between the R1 and R0 patient groups.

In a subgroup analysis, outcome in patients with node‐negative pancreatic cancer was significantly influenced by resection margin status. Therefore, in patients with clinical N0 disease, the role of the surgeon in achieving a radical resection is of great importance. Involvement of the large vessels should be evaluated carefully during surgery, as the vascular margin is the margin at greatest risk of tumour involvement. New molecular imaging modalities, such as fluorescence or photoacoustic imaging, could be used to improve the detection of tumour‐positive lymph nodes and may facilitate radical resection, especially at difficult margins including the posterior one[37](#bjs11115-bib-0037){ref-type="ref"}, [38](#bjs11115-bib-0038){ref-type="ref"}, [39](#bjs11115-bib-0039){ref-type="ref"}. These imaging techniques, with use of an exogenous agent directed against the tumour, allow the surgeon to image the lesion and may provide important additional information during the operation. In addition, molecular imaging may be beneficial in terms of disease staging. Contrast‐enhanced ultrasound imaging and/or tumour‐specific PET could be useful for preoperative detection of distant metastases and local staging[40](#bjs11115-bib-0040){ref-type="ref"}.

It is difficult to achieve a radical resection at the posterior surgical margin during pancreatoduodenectomy[4](#bjs11115-bib-0004){ref-type="ref"}, [25](#bjs11115-bib-0025){ref-type="ref"}, [41](#bjs11115-bib-0041){ref-type="ref"}. Vascular resection is an option to obtain a clear resection margin in locally advanced tumours. Therefore, an accurate method for detecting extension of the tumour before or during surgery is essential. Osipov and colleagues[25](#bjs11115-bib-0025){ref-type="ref"} included the posterior surface, vascular groove and uncinate margins in the definition of posterior margin, in accordance with criteria established by the AJCC. Their data are consistent with the present finding that the vascular margin was associated with clinical outcomes, albeit not significantly. In a recent study[10](#bjs11115-bib-0010){ref-type="ref"} of 1151 patients, a positive direct posterior resection margin was associated with reduced OS and recurrence‐free survival, whereas a positive direct superior mesenteric margin was associated with a higher local recurrence rate. For both margins, however, a R1 margin smaller than 1 mm did not affect clinically relevant outcomes. On the other hand, another study[42](#bjs11115-bib-0042){ref-type="ref"} reported that only the transection margin of the pancreatic neck and the superior mesenteric artery‐facing margin were associated with prognosis. At present, it is unclear why involvement of a specific margin would affect prognosis more than other margins; the answer may lie in differences in the density of blood vessels, nerves and/or lymphatic vessels surrounding the pancreas.

This study has shown that patients with tumour‐free resection margins have better survival than patients with involved resection margins after pancreatectomy. When the resection margin is involved, the vascular margin is most often the site of irradicality. Furthermore, because the overall distribution patterns of recurrence are similar after R0 and R1 resections, all patients may benefit from (neo)adjuvant treatment strategies. Moreover, achieving a radical resection can significantly change the outcome in patients with lymph node‐negative disease. Patients with suspected N0 disease should be identified, for example by improved imaging strategies; in these patients every attempt to achieve an R0 resection (for example by vascular resection) seems justified to achieve maximum local control.
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**Table S1** Factors associated with locoregional recurrence and distant metastases

**Table S2** Percentage of involved margins in patients with pancreatic cancer

**Fig. S1** Effect of vascular margin on (A) overall survival and (B) local recurrence in R0 and R1 patients. (C) Summary of the effect of resection margin on local recurrence and the time until recurrence in R0 and R1 patients

**Table S3** Summary of factors that affect overall survival in patients with pancreatic cancer
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Click here for additional data file.
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